AI will help physicians establish precise risk stratification and staging to guide selection of the right treatment in prostate cancer patients
AIRA Matrix announced a collaboration with Muljibhai Patel Urological Hospital, Nadiad (MPUH) and Gujarat Imaging Center, Ahmedabad (GIC).
The collaboration will enable the development of artificial intelligence-based solutions that provide information from radiological and histopathological data for precise risk stratification and institution of therapy in prostate cancer.
As part of this collaboration, the MPUH and GIC will provide expertise in the field of uro-oncology, histopathology and radiology and will work with the AIRA Matrix team to enable the development of a deep learning-based solution that increases multiparametric MRI (mpMRI) and histopathology reports.
While the histopathologic examination of a biopsy is the gold standard in the diagnosis and classification of prostate cancer, it is an invasive process that is burdensome on the patient and requires a delay. longer for the statement. In comparison, mpMRI is an important non-invasive modality in the diagnosis, staging and monitoring of prostate cancer with a shorter turnaround time. However, the accuracy of mpMRI for these procedures lags behind reports based on histopathology.
AIRA Matrix believes that the performance of mp MRI can be increased with the help of deep learning networks trained on the gold standard of histopathology. The objective of this collaboration is to combine Artificial Intelligence solutions trained using histopathology data to increase the sensitivity and specificity of non-invasive radiological investigations such as mmpMRI.
Chaith Kondragunta, CEO of AIRA Matrix, said: âOur goal is to use our technological expertise to improve prostate cancer screening, prognosis, treatment planning and monitoring, with better patient outcomes as well. than for caregivers. We are delighted and honored to work with leading experts in this field from MPUH and GIC and are excited about the opportunities to improve the prostate cancer care journey through this collaboration.
Renowned urologist Dr Mahesh Desai is leading the MPUH team in this important study with Dr Shailesh Soni and Dr Arvind Ganpule. The team notes that âmMRI and histopathology are the cornerstones to guide clinicians in different aspects of the management of prostate carcinoma. They help in the diagnosis, prognosis and to dictate monitoring protocols in the management of these patients. The addition of deep machine learning has the potential in the future to open up new perspectives in terms of filling knowledge gaps. This would potentially help the most important stakeholder in this conundrumâ¦ namely the patient. “
Dr. Hemant Patel, director of GIC and former president of the Indian Radiology Imaging Association (IRIA) added: care and lead the way for better diagnostic solutions in the future. Such collaborations can further bridge the gap between imaging and final histopathologic diagnosis.
Dr. Drushi Patel, consultant radiologist at the Gujarat Imaging Center (GIC), an expert in prostate MRI reports, said âProstate MRI has evolved into a non-invasive imaging tool. acceptable to guide management decisions and biopsy planning for prostate cancer. At GIC, we have been involved in providing the latest Onco imaging diagnostic solutions and share extensive experience for prostate magnetic resonance imaging in particular as it has evolved into its current role in clinical practice. .